Michael Brown serves as Executive Vice President and Chief Legal Officer at Dexcom Inc., a leading innovator in continuous glucose monitoring (CGM) technology. With over 25 years of experience in corporate law, particularly in the healthcare and medical device sectors, Brown joined Dexcom in 2015 after holding senior legal positions at prominent firms such as Medtronic and Johnson & Johnson. He earned his Juris Doctor from Harvard Law School and a Bachelor of Arts in Political Science from Stanford University, laying a strong foundation for his expertise in regulatory compliance, intellectual property, and mergers & acquisitions. At Dexcom, Brown has been instrumental in navigating complex regulatory landscapes, including successful FDA approvals for groundbreaking CGM products like the G7 system and Dexcom ONE. His leadership facilitated the company's $1.6 billion acquisition of TypeZero Technologies in 2018, enhancing Dexcom's automated insulin delivery capabilities. Brown's strategic oversight has also defended key patents against infringement claims, safeguarding Dexcom's market dominance and contributing to a stock value surge of over 500% during his tenure. Today, as CLO, Brown manages a global legal team responsible for corporate governance, risk management, and international expansion efforts into Europe and Asia. His proactive approach to ethical compliance and diversity initiatives has earned him recognition, including a spot on the National Law Journal's "Healthcare Trailblazers" list in 2022. Under his guidance, Dexcom continues to push boundaries in diabetes management, improving lives for millions worldwide.